MARCUS FINCH: Open Payments
NPI 1114969656 · PETAL, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$571 in 32 payments from 13 companies in 2025. Trend: 2023 $819 · 2024 $365 · 2025 $571
Food & beverage: $571
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 6 | $115 |
| Abbott Laboratories | 3 | $73 |
| Novo Nordisk Inc | 4 | $68 |
| Lilly USA, LLC | 4 | $64 |
| Amgen Inc. | 3 | $45 |
| PFIZER INC. | 2 | $42 |
| GlaxoSmithKline, LLC. | 2 | $31 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $31 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $30 |
| Exact Sciences Corporation | 1 | $21 |
Products named: QULIPTA, FREESTYLE LIBRE 3, MOUNJARO, REPATHA, CAPLYTA, JARDIANCE, PREVNAR 20, The Cologuard Plus Collection Kit.
Industry payments across MS — which companies pay providers there.
